Biotech Stocks Rally: ADXN Soars 71%, ENGN Jumps 26%, NTHI Gains 12%, PRQR Rises 10%
Biotech stocks ADXN, ENGN, NTHI, and PRQR rose significantly. ADXN surged 71% after its spin-out Neurosterix raised $105M. ENGN gained 26% with new executive appointments. NTHI rose 13% following FDA meeting news. PRQR increased 10% on strong revenue growth and clinical progress.
How this was made
The 30-second read
Why it matters
Collective news lifts sentiment in the small‑cap biotech space, but individual outcomes remain contingent on clinical and regulatory success.
Market read
Short‑term bullish bias for the highlighted tickers; sector‑wide rally possible if catalysts hold.
What to watch
Dilution from the $105M raise and cash burn rates could pressure valuations if milestones are delayed.
Background
The article aggregates recent positive catalysts across four biotech companies, each reporting financing, executive hires, FDA engagement, or revenue growth.
Ticker impact
Addex Therapeutics announced a $105M Series B financing for its spin‑out Neurosterix, driving a 71% share surge.
likely upward pressure as investors price in the capital raise and retained equity stake.
Large raise for a micro‑cap biotech with immediate share reaction; market perceives growth catalyst.
enGene Therapeutics appointed a new CMO and CLO ahead of a planned BLA filing, sending the stock up 26%.
moderate upside as the market values the strengthened team and upcoming BLA.
Hiring is material for a pre‑approval biotech, but impact depends on regulatory outcome.
NeOnc Technologies received an FDA Type B End‑of‑Phase meeting to discuss accelerated approval for NEO100, lifting the stock 13%.
upward pressure as investors anticipate potential fast‑track approval.
Regulatory engagement is a key catalyst for a small biotech; magnitude depends on meeting outcome.
ProQR Therapeutics reported Q3 2026 revenue up 78.9% YoY and strong cash runway, moving the stock up 10%.
moderate upside as the market rewards revenue growth despite widening loss.
Revenue growth is material for a cash‑burn biotech; loss widening tempers enthusiasm.
Market effects
Biotech sector may see broader optimism as multiple small caps announce financing and regulatory progress.
U.S. biotech micro‑caps gain momentum, potentially lifting related ETFs.
Limited to niche biotech investors; no broad macro impact.
Counterpoint
Financing and regulatory milestones may not translate into long‑term value if clinical data later disappoint.
Key entities
- companyAddex Therapeutics
Biotech firm raising capital for spin‑out Neurosterix.
- companyenGene Therapeutics
Gene‑therapy developer adding senior executives.
- companyNeOnc Technologies
Oncology biotech securing FDA meeting.
- companyProQR Therapeutics
RNA‑therapy company reporting strong Q3 revenue.
